G6PD is usually upregulated in solid tumors and is associated with poor prognosis, making it a potential therapeutic target for cancer (Nagashio et al., 2019; Wang et al., 2021; Wang et al., 2020; Ramirez-Nava et al., 2021; Sun et al., 2021). Here, G6PD is linked to cancer.